News

Clinical Cancer Research 14, p. 1002-1014, February 15, 2008. Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression, Vyomesh Patel et al. (abstract)

Expression Pathology Aids Research in Identifying Biomarkers of Lung Cancer Metastasis and Survival, Feb. 19, 2008: Researchers at Tokyo Medical University, using Expression Pathology’s tissue microproteomics technologies, identified protein biomarkers associated with lung cancer metastasis, which were further studied for correlation to clinical outcomes. (more)

Expression Pathology Obtains Maryland Funding to Develop Breast Cancer Test, Feb. 6, 2008: Expression Pathology Inc. (EPI), a leader in tissue protein analysis, has obtained $125,000 from the State of Maryland to develop a quantitative test for HER2 protein, an important biomarker in breast cancer tissue samples. The funding is part of the Maryland Technology Development Corporation’s Maryland Technology Transfer Fund (TEDCO MTTF) and the Maryland Venture Fund’s Challenge Investment Program. (press release)

Lecia Microsystems to sell DIRECTOR laser microdissection slides, Sept. 10, 2007: Rapid, gentle and contamination free laser microdissection, directly into sample buffer, is now possible with the combination of Leica Microsystems’ state-of-the-art laser microdissection system Leica LMD6000 and Expression Pathology’s innovative DIRECTOR™ glass slides. A sales agreement between the two companies now gives scientists the opportunity to buy both the instrument and the slides from Leica Microsystems worldwide. (press release)

Expression Pathology Inc. and ORIDIS Biomed announce tissue proteomic alliance, May 3, 2007:The relationship combines Expression Pathology’s proprietary Liquid Tissue® and DIRECTOR™ technologies, which enable mass spectrometry-based discovery and measurement of protein biomarkers in archival tissue, with ORIDIS Biomed’s TISSOMICS™ research platform for high-throughput analysis of healthy and diseased patient tissue and its access to formalin-fixed tissue samples associated with longitudinal clinical and pathology information. (press release)

Publications

Clinical Cancer Research 14, p. 1002-1014, February 15, 2008. Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression, Vyomesh Patel et al. (abstract) (white paper summary)
Prieto, D.A., Hood, B.L., Darfler, M.M., Guiel, T.G., Lucas, D.A., Conrads, T.P., Veenstra, T.D. and Krizman, D. B. (2005) Biotechniques 38, S32 - S35)
Hood, B.L., Darfler, M.M., Guiel, T.G., Furusato, B., Lucas, D.A., Ringeisen, B.R., Sesterhenn, I.A., Conrads, T.P., Veenstra, T.D. and Krizman, D. B. (2005) Mol. Cell. Proteomics 4, 1741-1753

Conferences

2008

ASMS, Denver, June 1-5. (link) Booth 21. Register for our tissue proteomic luncheon, Wednesday, June 4.

American Association of Cancer Research, San Diego, April 12-16. (link) Booth 2428. See three posters using our technology; discovery of endometrial cancer markers (abstract), metastasis marker in melanoma (abstract ), protein biomarkers relating to metastasis and disease progression in lung cancer (abstract).

US and Canadian Association of Pathology, Denver, Mar. 1-7: Application of a Global Proteomic Approach to Archival Precursor Lesions: Upregulation of DMBT-1 and TG2 in Pancreatic Cancer Precursors (link)

Soc. of Surgical Oncology, Chicago, Mar. 13-16: Identification of Prognostic Biomarkers in Patients with Resectable Pancreas Cancer Using Formalin-fixed Tissue, Marcus Tan, MD, Washington University School of Medicine, St. Louis, MO (link)

SUBSCRIBE to our mailing list : stay informed about news and events in tissue proteomics.

Expression Pathology Inc. (EPI) is a leader in tissue microproteomics. Our technologies make possible mass spec protein analysis of formalin-fixed tissue, enabling discovery, validation and routine measurement of protein biomarkers related to clinical outcomes. Our near-term mission is to offer breakthrough research tools and collaborations to improve drug and diagnostic development and for basic research. Our proprietary technologies also provide the foundation for a whole new platform of tissue diagnostic tests currently under development.

The Liquid Tissue® MS protocol prepares FFPE samples for mass spec analysis. Complete solubilization captures the entire protein content. Mass spec friendly. Requires only 30,000 cells for multiple mass spectrometry analyses.

The Director™ Laser Microdissection Slides provide the fastest, easiest and most accurate way to collect specific cellular features from tissue sections. Engineered for use with existing Leica LMD and PALM Zeiss laser microdissection system.